Copyright
©The Author(s) 2023.
World J Clin Cases. Feb 16, 2023; 11(5): 1058-1067
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Published online Feb 16, 2023. doi: 10.12998/wjcc.v11.i5.1058
Table 6 Comparison of adverse reactions in each group, n (%)
| Group | Rash | Osteoporosis | Recurrence | Overall incidence |
| Control (n = 50) | 2 (4.00) | 3 (6.00) | 3 (6.00) | 13 (26.00) |
| Observation (n = 75) | 4 (5.33) | 4 (5.33) | 6 (8.00) | 17 (22.67) |
| χ2 | 0.932 | 0.874 | 0.672 | 0.961 |
| P value | 0.733 | 0.812 | 0.944 | 0.111 |
- Citation: Liang JJ, Feng WJ, Li R, Xu RT, Liang YL. Analysis of the value and safety of thyroid-stimulating hormone in the clinical efficacy of patients with thyroid cancer. World J Clin Cases 2023; 11(5): 1058-1067
- URL: https://www.wjgnet.com/2307-8960/full/v11/i5/1058.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i5.1058